MedWatch

Audientes reaches out to market for help in rights issue

A year involving a couple of downgrades was not what the Danish hearing firm had in mind when 2022 began. Now, Audientes must raise DKK 24.3m (USD 3.3m) to keep going for another twelve months.

Steen Thygesen, CEO of Audientes | Photo: Audientes / PR

Audientes, which has one self-fitting hearing aid on the market, is strapped for cash, and is reaching out to the stock market for help.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs